The U.S. drugmaker said two large trials of the oral antiviral being developed with Ridgeback Biotherapeutics would begin in September. Merck said it can manufacture “many millions of doses” of the drug before year end. Gilead Sciences Inc’s intravenous antiviral remdesivir is currently being widely used as a treatment for hospitalized COVID-19 patients.
from Yahoo Finance https://ift.tt/2ExMX6N
Leave a Reply